Introduction: Due to the rarity of ovarian carcinosarcomas, the optimal chemotherapeutic regimen to treat this aggressive disease is yet to be determined. The purpose of this study was to determine the response rate, recurrence-free survival, and overall survival of patients with ovarian carcinosarcoma who were treated with the combination of platinum and a taxane as first-line chemotherapy.
Methods: We identified all patients with ovarian carcinosarcoma who received a combination of platinum and taxane either after initial tumor resection or as neoadjuvant therapy. Data extracted from the medical records included residual tumor after surgery, number, type and dose of chemotherapy cycles, tumor response, and survival outcome.
Results: Between 1991 and 2005, 30 patients were identified for analysis. Twenty-four patients had stage III disease, 5 had stage IV disease, and 1 had stage II disease. All patients underwent surgical resection and 17 (57%) were cytoreduced to less than 1 cm. Twenty-eight patients received chemotherapy after surgery, and 2 patients received chemotherapy before surgery. Twenty-four patients (80%) received carboplatin and paclitaxel, 3 (10%) received carboplatin and docetaxel, and 3 (10%) received cisplatin and paclitaxel. Twelve (40%) had a complete response, 7 (23%) a partial response, 2 (7%) stable disease, and 9 (30%) progression of disease. The median time to progression for responders was 12 months. With a median follow-up of 23 months, the median overall survival was 43 months for survivors. The 3- and 5-year survival rates were 53% and 30%, respectively.
Conclusion: The combination of platinum and a taxane is a viable first-line treatment option for patients with ovarian carcinosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2007.01.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer.
Taiwan J Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. Electronic address:
Objective: To investigate the real-world efficacy and toxicity of paclitaxel-cisplatin-bevacizumab and identify prognostic factors for paclitaxel-cisplatin-bevacizumab in platinum-naïve primary stage IVB cervical cancer.
Materials And Methods: We retrospectively reviewed patients with stage IVB cervical cancer who received paclitaxel-cisplatin-bevacizumab as first-line treatment between July 2015 and December 2021 at Asan Medical Center, Korea. Patient data including clinicopathologic characteristics, imaging, paclitaxel-cisplatin-bevacizumab administration, recurrence, and survival were collected.
Electrotherapy as treatment for chemotherapy-induced peripheral neuropathy - a randomized controlled trial.
Front Neurol
December 2024
IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.
Background: Electrotherapy has been investigated in chronic pain and diabetic peripheral neuropathy, however prospective trials in patients with chemotherapy-induced peripheral neuropathy (CIPN) are scarce.
Methods: Fifty-one patients with CIPN ≥ grade 1 subsequent to receiving platinum- and/or taxane-based chemotherapy types were randomized to 8 weeks of high tone external muscle stimulation (HTEMS) or transcutaneous electrical nerve stimulation (TENS). The primary outcome were changes in the EORTC-QLQ-CIPN20 questionnaire.
Case report: Complete response in TMB-H advanced uterine clear cell carcinoma: a case analysis of paclitaxel albumin-bound combined with PD-1/CTLA-4 bispecific antibody.
Front Immunol
January 2025
The Oncology Department of the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Background: Uterine clear cell carcinoma (UCCC) is a rare and aggressive subtype of endometrial cancer, often presenting at an advanced stage with poor prognosis. Treatment options for advanced or recurrent UCCC are currently limited, especially after platinum-based chemotherapy has failed.
Case Presentation: We present the case of a 49-year-old female diagnosed with stage IV uterine clear cell carcinoma.
Visual loss following secondary retinitis pigmentosa (RP) is a rare complication of cytotoxic chemotherapy. Few cases of docetaxel- and/or platinum-induced retinal toxicity have been reported. Routine ocular examination of patients undergoing chemotherapy is required for early recognition and intervention of ocular toxicity.
View Article and Find Full Text PDFEstablishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79.
Int J Mol Sci
December 2024
Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
High-grade serous ovarian carcinoma (HGSOC) remains the most common and deadly form of ovarian cancer. However, available cell lines usually fail to appropriately represent its complex molecular and histological features. To overcome this drawback, we established OVAR79, a new cell line derived from the ascitic fluid of a patient with a diagnosis of HGSOC, which adds a unique set of properties to the study of ovarian cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!